

## Research Article

# Simultaneous Nasopharyngeal Carriage of Two Pneumococcal Multilocus Sequence Types with a Serotype 3 Phenotype

Donald Inverarity,<sup>1</sup> Mathew Diggle,<sup>2</sup> Roisin Ure,<sup>3</sup> Diego Santana-Hernandez,<sup>4</sup>  
Peter Altstadt,<sup>5</sup> Timothy Mitchell,<sup>6</sup> and Giles Edwards<sup>3</sup>

<sup>1</sup>Monkland Hospital, Clinical Microbiology Department, Monklands General Hospital, Monkscourt Avenue, Airdrie, Lanarkshire ML5 0JS, UK

<sup>2</sup>Queens Medical Centre, Department of Clinical Microbiology, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham NG7 2UH, UK

<sup>3</sup>Scottish Haemophilus, Legionella, Meningococcal and Pneumococcal Reference Laboratory (SHLMPRL), Stobhill Hospital, Glasgow G21 3UW, UK

<sup>4</sup>Fundación Totatí, Casilla 158, Trinidad, Beni, Bolivia

<sup>5</sup>Laboratorios Altstadt, Casilla 158, Trinidad, Beni, Bolivia

<sup>6</sup>Institute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre University of Glasgow, College of Medical, Veterinary and Life Sciences, 120 University Place, Glasgow G12 8TA, UK

Correspondence should be addressed to Donald Inverarity, donald.inverarity@lanarkshire.scot.nhs.uk

Received 14 January 2010; Revised 26 September 2010; Accepted 13 October 2010

Academic Editor: Eduardo Dei-Cas

Copyright © 2010 Donald Inverarity et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Knowledge of the epidemiology of pneumococcal disease in Bolivia is sparse, and Multilocus Sequence Typing (MLST) of isolates has not been previously possible. Beni state has until recently been a geographically isolated region of the Bolivian Amazon basin and is a region of significant poverty. During June and July 2007, we performed a pneumococcal carriage study recruiting over 600 schoolchildren in two towns in the Beni state. Here, we describe the unique identification of simultaneous nasopharyngeal carriage of two pneumococcal multilocus sequence types with a serotype 3 phenotype within a single subject.

## 1. Introduction

Multilocus sequence typing (MLST) is an internationally utilized method for the molecular categorization of *Streptococcus pneumoniae* (the pneumococcus) [1]. Pneumococci predominantly colonise the human nasopharynx and in the vast majority of instances do not progress to cause invasive disease. In the first two years of life, 95% of children can be colonized with pneumococci and 73% can acquire at least two different serotypes, although these are carried on different occasions. Data relating to multiple colonisation is limited; however, the range of multiple colonisation when studied can vary dramatically from 1.3% to 30%. It is important to note that a number of different factors could influence this, including, geographical locations, social and

economic factors, and sample technique [2–4]. Nasopharyngeal colonization can begin as early as the day of birth. The duration of carriage for a particular serotype is commonly 2.5 to 4.5 months, and the duration of carriage decreases with each successive pneumococcal serotype. This duration of carriage is inversely correlated with age [4] as pneumococcal carriage declines as children grow older [5]. Although it is well documented that multiple different serotypes (and consequently multiple sequence types) of pneumococci may be carried in the nasopharynx concurrently, we are unaware of any descriptions of multiple sequence types of the same serotype being identified simultaneously at this site.

As part of a study of pneumococcal carriage among schoolchildren from the Beni region of Bolivia during June and July 2007, we performed a pneumococcal carriage study

recruiting over 600 schoolchildren in two towns in the Beni state. Here, we describe the unique identification of simultaneous nasopharyngeal carriage of two pneumococcal multilocus sequence types with a serotype 3 phenotype within a single subject.

## 2. Materials and Methods

This study was designed in accordance with the standard method of the WHO working group [6] and an earlier method devised by PAHO for a Latin American context <http://www.paho.org/spanish/ad/ths/ev/LABS-manual-vigilancia-serotipos.pdf> {accessed 10th of October 2008}. Dacron polyester-tipped swabs (Medical Wire and Equipment, UK) were couriered from the United Kingdom for nasopharyngeal swabbing as were Skim Milk Tryptone Glucose Glycerin (STGG) broth media [7] which had been manufactured, sterilized, and quality controlled as 1 ml aliquots at the Scottish Haemophilus, Legionella, Meningococcal, and Pneumococcal Reference Laboratory (SHLMPRL) in cryotubes (Sarstedt AG & Co., Germany) to be used as a short-term transport media and storage media at  $-20^{\circ}\text{C}$ .

Five percent horse blood agar (E & O Media Services Limited, United Kingdom) was couriered from the United Kingdom as were optochin discs (Oxoid, United Kingdom) and Transwabs (TSCswabs, United Kingdom). The use of 5% horse blood rather than blood agar with gentamicin [8], colistin-nalidixic acid, or colistin-oxolinic acid was a necessary deviation from the published standard method [6].

Nasopharyngeal swabs were taken by an experienced otolaryngologist (Dr. Santana-Hernandez). If nasopharyngeal swabbing was not tolerated or not possible in younger children, oropharyngeal swabs were performed. The tips of the swabs were then cut off and stored in STGG and either plated onto 5% horse blood agar on the same day or stored at  $-20^{\circ}\text{C}$  until cultured. After incubation, alpha haemolytic colonies were subcultured onto 5% horse blood agar for optochin susceptibility testing. Incubation was performed at  $37^{\circ}\text{C}$  in a carbon dioxide-enriched atmosphere using candle jars at Laboratorios Altstadt, Trinidad, Bolivia.

Pure cultures of presumed pneumococci were stored at room temperature on Transwabs (TSCswabs, United Kingdom) until ready for transportation to SHLMPRL by air [9].

Facilities for serotyping in Latin America are sparse [10], and it is not possible to perform MLST in Bolivia. Transportation of isolates from Trinidad, Bolivia to Glasgow, United Kingdom took 42 days on Transwabs under conditions which were not environmentally controlled.

Blood agar with neomycin (Oxoid, United Kingdom) was used at SHLMPRL to culture isolates received on Transwabs for 48 hours under anaerobic conditions. Isolates which had survived transportation were further subcultured on 5% horse blood agar and stored at  $-80^{\circ}$  on Protect beads (TSC Ltd, United Kingdom).

The whole process of serotyping of strains was performed at SHLMPRL using a coagglutination method [11] utilising sera from Statens Serum Institut, Denmark.

MLST was performed on these isolates as described previously [12–14]. Briefly, fragments from the seven housekeeping genes, *aroE*, *gdh*, *gki*, *recP*, *spi*, *xpt*, and *ddl* were amplified from the pneumococcal lysate with the primers described by Enright and Spratt [13] by using a single PCR reaction. The amplified DNA was cleaned as previously described [12, 15]. The cleaned amplified DNA was then sequenced with the same primer set using the DYEnamic ET Terminator sequencing kit (Amersham Biosciences, Little Chalfont, United Kingdom). The subsequent sequenced DNA was cleaned as previously described [12, 15]. These procedures were carried out on a liquid handling robotic platform (MWG-Biotech, Milton Keynes, United Kingdom) and a MegaBACE 1000 DNA sequencer (Amersham Biosciences). The analysis of the sequence data and the subsequent assignment of a sequence type (ST) were performed as described previously [16]. Further analysis of relationships between this and other pneumococcal STs was performed using the BURST (Based Upon Related Sequence Types) program [17].

## 3. Results

This pneumococcal carriage study was conducted among schoolchildren from the Beni region of Bolivia, and during this study we identified a 9-year-old girl with mucoid pneumococci present in the nasopharynx. Colonies of this single mucoid phenotype consistently were identified as serotype 3 using a coagglutination method [11]. MLST was performed on two separate colonies which were indistinguishable morphologically and identified one as Sequence Type 180 (ST180) and the other as ST1989. These sequence types differ by two of the seven housekeeping genes used in the MLST scheme. Sequence Type 1989 (ST1989) and ST180 exist as double-locus variants within the same clonal complex. ST1989 may possibly have arisen from ST2311 which may have arisen from ST180. The single-nucleotide polymorphisms (SNPs) in the *xpt* and *gdh* alleles account for these differences in sequence type.

## 4. Discussion

Serotype 3 pneumococci are morphologically distinct from most other serotypes of pneumococci due to their mucoid capsule [18]. It has been determined that duplications in the *cap3A* gene in the type 3 capsule locus are associated with high-frequency phase variation [19] which relates to capsular and acapsular (rough) phase variants [20].

This mucoid serotype is also a common cause of acute otitis media [20, 21], particularly ST180 [22], where biofilm formation may be important in the pathogenesis of this manifestation. Also, Serotype 3 pneumococci cause acute conjunctivitis, and it is postulated that this serotype possesses virulence factors which predispose it to mucosal sites [21]. In addition, Serotype 3 is associated with an increased relative risk of death from invasive pneumococcal disease in Swedish adults [23], but in children, Serotype 3 ST180 pneumococci have been identified as having odds of invasiveness of only 0.1 which was significantly associated

<i>gdh</i> 5	AGAACACTTT	ATCCGTGGGC	AATACCGCTC	TGTAAGATT	40	<i>xpt</i> 1	GGTGATAACA	TCCTCAAGGT	AGATTCTTTT	TTAACCCACC	40
<i>gdh</i> 15	-----	-----A-	-----	-----	40	<i>xpt</i> 3	-----	-----	-----	-----	40
<i>gdh</i> 5	GATGGCATGA	AATACATCTC	TTATCGTAGC	GAGCCAAATG	80	<i>xpt</i> 1	AAGTTGACTT	TAGCTTGATG	CGAGAGATTG	GTAAGGTTTT	80
<i>gdh</i> 15	-----	-----	-----	--A-----	80	<i>xpt</i> 3	-----	-----	-----	-----	80
<i>gdh</i> 5	TGAATCCAGA	ATCAACAAC	GAAACCTTTA	CATCTGGTGC	120	<i>xpt</i> 1	TGCGGAAAAA	TTTGCTGCTA	CTGGCATTAC	CAAGTTCGTA	120
<i>gdh</i> 15	-----	-----	-----	-----	120	<i>xpt</i> 3	-----	-----G	-----	-----	120
<i>gdh</i> 5	CTTCTTTGTA	GACAGCGATC	GATTCCGTGG	TGTTCCTTTC	160	<i>xpt</i> 1	ACCATTGAAG	CGTCGGGTAT	TGCCCCAGCC	GTTTTTACAG	160
<i>gdh</i> 15	-----	-----	-----	-----	160	<i>xpt</i> 3	-----	-----	-----	-----	160
<i>gdh</i> 5	TTTTTCCGTA	CAGGTAACG	ACTGACTGAA	AAAGGAACTC	200	<i>xpt</i> 1	CTGAAGCCTT	AAACGTTCCC	ATGATTTTCG	CCAAAAAAGC	200
<i>gdh</i> 15	-----	-----	-----	-----	200	<i>xpt</i> 3	-----	-----	-----	-----	200
<i>gdh</i> 5	ATGTCAACAT	CGTCTTTAAA	CAAATGGATT	CTATCTTTGG	240	<i>xpt</i> 1	TAAGAACATC	ACCATGAACG	AAGGCATCTT	AACTGCTCAA	240
<i>gdh</i> 15	-----	-----	-----	---A-----	240	<i>xpt</i> 3	-----	-----	-----	-----	240
<i>gdh</i> 5	AGAACCACCT	GCTCCAATA	TTTTGACCAT	CTATATTCAA	280	<i>xpt</i> 1	GTCTACTCCT	TTACCAAGCA	GGTGACCAGC	ACTGTTTCTA	280
<i>gdh</i> 15	-----	-----	-----	-----	280	<i>xpt</i> 3	-----	-----	-----	-----	280
<i>gdh</i> 5	CCAACAGAAG	GCTTCTCTCT	TAGCCTAAAT	GGGAAGCAAG	320	<i>xpt</i> 1	TCGCTGGAAA	ATTCTCTCA	CCAGAGGACA	AGGTTTTGAT	320
<i>gdh</i> 15	-----	-----	-----	-----	320	<i>xpt</i> 3	-----	-----	-----	-----	320
<i>gdh</i> 5	TAGGAGAAGA	ATTTAACTTG	GCTCCTAACT	CACTTGATTA	360	<i>xpt</i> 1	TATCGACGAT	TTCCTTGCTA	ATGGCCAAGC	TGCTAAAGGC	360
<i>gdh</i> 15	-----	-----	-----	-----	360	<i>xpt</i> 3	-----	-----	-----	-----	360
<i>gdh</i> 5	CCGTACAGAT	GCGACTGCAA	CTGGTGCTTC	TCCAGAACCA	400	<i>xpt</i> 1	TTGATTCAAA	TCATCGAACA	GGCCGGTGCC	ACAGTCCAAG	400
<i>gdh</i> 15	T-----C	-----	-----	-----	400	<i>xpt</i> 3	-----	-----	-----	-----	400
<i>gdh</i> 5	TACGAAAAAT	TGATTTATGA	TGTCCTAAAT	AACAACCTCAA	440	<i>xpt</i> 1	CTATCGGTAT	CGTGATTGAG	AAATCCTTCC	AAGATGGTCG	440
<i>gdh</i> 15	-----G-----	-----	-----	-----	440	<i>xpt</i> 3	-----	-----	-----	-----	440
<i>gdh</i> 5	CTAACTTTAG	CCACTGGGAT	460			<i>xpt</i> 1	TGATTGCTT	GAAAAAGCAG	GCTACCTGT	CCTATCACTT	480
<i>gdh</i> 15	-----	-----	460			<i>xpt</i> 3	-----	-----	-----	-----	480
						<i>xpt</i> 1	GCTCGC	486			
						<i>xpt</i> 3	-----	486			

FIGURE 1: Alignment of sequences for alleles *xpt* and *gdh* for ST1989 and ST180 demonstrating one SNP difference in the *xpt* gene at position 100 and six SNP differences in the *gdh* gene at positions 19, 73, 235, 361, 370, and 406.

with asymptomatic carriage [24]. Due to the limited data, the odds ratio of the newly identified ST-1989 is unknown. The dichotomy that Serotype 3 pneumococci can cause disease with a high associated mortality in some individuals while being harmlessly carried in the nasopharynx of others has been recognised since the early 20th century [25]. An association between Serotype 3 pneumococci causing disease more commonly in the elderly than in children is also an established observation [25]. Serotype 3 isolates of different genotypes may also have different virulence in mice [26, 27].

We believe that this discovery of a population of double locus variants expressing the Serotype 3 capsules concurrently in a human host is suggestive of a number of different events. It is possible that multiple spontaneous mutations resulting in single nucleotide polymorphisms occur naturally within nasopharyngeal populations of pneumococci which, in a natural biofilm environment, may be contributing to genetic diversity and genetic exchange *in vivo*. This could result in altered interactions between the Serotype 3 pneumococcal populations and their hosts

depending on which genotype was predominant, and it is possible that this might influence disease manifestation and outcome. Moreover, it is possible that these variants diverged from a single genetic source long before acquisition by this host and subsequent isolation and characterization. Therefore, although these findings are valuable within the context of such a unique geographic location and social and economic environment, this data is limited and further follow-up studies would be required to support any of these findings.

## Acknowledgments

The authors wish to acknowledge the assistance and generosity of individuals and organizations without whom this project would not have been possible. These include the staff of Fundación Totaí, Mrs Adelina Altstadt of Laboratorios Altstadt, the staff of SHLMPRL, the staff of the Meningococcal Reference Laboratory, Madrid and Inbolpak S.R.L for assisting with transportation of isolates to Scotland,

Meningitis Association Scotland for funding, and Medical Wire & Equipment for the donation of nasopharyngeal swabs.

## References

- [1] M. C. Enright and B. G. Spratt, "A multilocus sequence typing scheme for *Streptococcus pneumoniae*: identification of clones associated with serious invasive disease," *Microbiology*, vol. 144, no. 11, pp. 3049–3060, 1998.
- [2] S. Obaro and R. Adegbola, "The pneumococcus: carriage, disease and conjugate vaccines," *Journal of Medical Microbiology*, vol. 51, no. 2, pp. 98–104, 2002.
- [3] S. D. Brugger, P. Frey, S. Aebi, J. Hinds, and K. Mühlemann, "Multiple colonization with *S. pneumoniae* before and after introduction of the seven-valent conjugated pneumococcal polysaccharide vaccine," *PLoS ONE*, vol. 5, no. 7, Article ID e11638, 8 pages, 2010.
- [4] B. M. Gray, G. M. Converse III, and H. C. Dillon Jr., "Epidemiologic studies of *Streptococcus pneumoniae* in infants: acquisition, carriage, and infection during the first 24 months of life," *Journal of Infectious Diseases*, vol. 142, no. 6, pp. 923–933, 1980.
- [5] D. Bogaert, R. De Groot, and P. W. M. Hermans, "*Streptococcus pneumoniae* colonisation: the key to pneumococcal disease," *Lancet Infectious Diseases*, vol. 4, no. 3, pp. 144–154, 2004.
- [6] K. L. O'Brien and H. Nohynek, "Report from a WHO Working Group: standard method for detecting upper respiratory carriage of *Streptococcus pneumoniae*," *The Pediatric Infectious Disease Journal*, vol. 22, no. 2, pp. e1–e11, 2003.
- [7] K. L. O'Brien, M. A. Bronsdon, R. Dagan et al., "Evaluation of a medium (STGG) for transport and optimal recovery of *Streptococcus pneumoniae* from nasopharyngeal secretions collected during field studies," *Journal of Clinical Microbiology*, vol. 39, no. 3, pp. 1021–1024, 2001.
- [8] G. M. Converse III and H. C. Dillon Jr., "Epidemiological studies of *Streptococcus pneumoniae* in infants: methods of isolating pneumococci," *Journal of Clinical Microbiology*, vol. 5, no. 3, pp. 293–296, 1977.
- [9] D. Inverarity, M. Diggle, G. Edwards, and T. Mitchell, "An evaluation of media suitable for the transportation by air of *Streptococcus pneumoniae* isolates," *Journal of Infection*, vol. 55, pp. e65–e66, 2007.
- [10] P. Camargos, G. B. Fischer, H. Mocelin, C. Dias, and R. Ruvinsky, "Penicillin resistance and serotyping of *Streptococcus pneumoniae* in Latin America," *Paediatric Respiratory Reviews*, vol. 7, no. 3, pp. 209–214, 2006.
- [11] L. E. Smart, "Serotyping of *Streptococcus pneumoniae* strains by coagglutination," *Journal of Clinical Pathology*, vol. 39, no. 3, pp. 328–331, 1986.
- [12] S. C. Clarke and M. A. Diggle, "Automated PCR/sequence template purification," *Molecular Biotechnology*, vol. 21, no. 3, pp. 221–224, 2002.
- [13] M. C. Enright and B. G. Spratt, "A multilocus sequence typing scheme for *Streptococcus pneumoniae*: identification of clones associated with serious invasive disease," *Microbiology*, vol. 144, no. 11, pp. 3049–3060, 1998.
- [14] J. Jefferies, S. C. Clarke, M. A. Diggle, A. Smith, C. Dowson, and T. Mitchell, "Automated pneumococcal MLST using liquid-handling robotics and a capillary DNA sequencer," *Molecular Biotechnology*, vol. 24, no. 3, pp. 303–307, 2003.
- [15] C. B. Sullivan, J. M. C. Jefferies, M. A. Diggle, and S. C. Clarke, "Automation of MLST using third-generation liquid-handling technology," *Molecular Biotechnology*, vol. 32, no. 3, pp. 219–225, 2006.
- [16] M. A. Diggle and S. C. Clarke, "Rapid assignment of nucleotide sequence data to allele types for multi-locus sequence analysis (MLSA) of bacteria using an adapted database and modified alignment program," *Journal of Molecular Microbiology and Biotechnology*, vol. 4, no. 6, pp. 515–517, 2002.
- [17] E. J. Feil, B. C. Li, D. M. Aanensen, W. P. Hanage, and B. G. Spratt, "eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data," *Journal of Bacteriology*, vol. 186, no. 5, pp. 1518–1530, 2004.
- [18] H. Schottmuller, "Die Artunterscheidung der für den Menschen pathogenen Streptokokken durch Blutagar," *Munchen Medical Wochenschr*, vol. 50, p. 908, 1903.
- [19] R. D. Waite, J. K. Struthers, and C. G. Dowson, "Spontaneous sequence duplication within an open reading frame of the pneumococcal type 3 capsule locus causes high-frequency phase variation," *Molecular Microbiology*, vol. 42, no. 5, pp. 1223–1232, 2001.
- [20] M. C. McEllistrem, J. V. Ransford, and S. A. Khan, "Characterization of *in vitro* biofilm-associated pneumococcal phase variants of a clinically relevant serotype 3 clone," *Journal of Clinical Microbiology*, vol. 45, no. 1, pp. 97–101, 2007.
- [21] D. S. Shouval, D. Greenberg, N. Givon-Lavi, N. Porat, and R. Dagan, "Site-specific disease potential of individual *Streptococcus pneumoniae* serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis," *Pediatric Infectious Disease Journal*, vol. 25, no. 7, pp. 602–607, 2006.
- [22] M. C. McEllistrem, J. M. Adams, K. Patel et al., "Acute otitis media due to penicillin-nonsusceptible *Streptococcus pneumoniae* before and after the introduction of the pneumococcal conjugate vaccine," *Clinical Infectious Diseases*, vol. 40, no. 12, pp. 1738–1744, 2005.
- [23] P. Martens, S. W. Worm, B. Lundgren, H. B. Konradsen, and T. Benfield, "Serotype-specific mortality from invasive *Streptococcus pneumoniae* disease revisited," *BMC Infectious Diseases*, vol. 4, article 21, 2004.
- [24] A. B. Brueggemann, D. T. Griffiths, E. Meats, T. Peto, D. W. Crook, and B. G. Spratt, "Clonal relationships between invasive and carriage *Streptococcus pneumoniae* and serotype- and clone-specific differences in invasive disease potential," *Journal of Infectious Diseases*, vol. 187, no. 9, pp. 1424–1432, 2003.
- [25] F. G. Blake, "Observations on pneumococcus type III pneumonia," *Annals of Internal Medicine*, vol. 5, pp. 673–686, 1931.
- [26] T. Kelly, J. P. Dillard, and J. Yother, "Effect of genetic switching of capsular type on virulence of *Streptococcus pneumoniae*," *Infection and Immunity*, vol. 62, no. 5, pp. 1813–1819, 1994.
- [27] B. Ren, A. J. Szalai, O. Thomas, S. K. Hollingshead, and D. E. Briles, "Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of *Streptococcus pneumoniae*," *Infection and Immunity*, vol. 71, no. 1, pp. 75–85, 2003.